Article citationsMore>>

C. Buske, E. Hoster and M. Dreyling, “German LowGrade Lymphoma Study Group. The Addition of Rituximab to Front-Line Therapy with CHOP (R-CHOP) Results in a Higher Response Rate and Longer Time to Treatment Failure in Patients with Lymphoplasmacytic Lymphoma: Results of a Randomized Trial of the German Low-Grade Lymphoma Study Group (GLSG),” Leukemia, Vol. 23, No. 1, 2009, pp. 153-161. doi:10.1038/leu.2008.261

has been cited by the following article:

Follow SCIRP
Twitter Facebook Linkedin Weibo
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top